DURECT (DRRX) Q1 2025 earnings summary

Executive summary

• DURECT is a late-stage biopharmaceutical company focused on epigenetic therapies, with larsucosterol as its lead candidate for alcohol-associated hepatitis (AH) and metabolic dysfunction-associated steatohepatitis (MASH).

• Planning a registrational Phase 3 trial for larsucosterol in AH, with topline results expected within two years of trial initiation, contingent on securing sufficient funding.

• Phase 2b AHFIRM trial results for larsucosterol published in NEJM Evidence in January 2025, providing validation for the planned Phase 3 trial design.

• In November 2024, DURECT sold its ALZET product line for $17.5 million and paid off its term loan, focusing resources on core R&D.

• Innocoll Pharmaceuticals transferred all data and know-how related to POSIMIR after licensing agreement termination; evaluating new commercialization partners.

Financial highlights

• Net loss for Q1 2025 was $4.2 million, an improvement from $7.6 million in Q1 2024, mainly due to lower R&D expenses.

• Total revenues were $321,000 in Q1 2025, down from $496,000 in Q1 2024, primarily due to lower earn-out revenue from Indivior.

• Cash, cash equivalents, and investments totaled $8.4 million as of March 31, 2025, down from $12.0 million at year-end 2024.

• Operating expenses decreased to $4.5 million in Q1 2025 from $6.8 million in Q1 2024.

• Research and development expenses decreased to $1.9 million in Q1 2025 from $4.1 million in Q1 2024, reflecting reduced larsucosterol program costs and headcount.

Outlook and guidance

• DURECT plans to initiate a Phase 3 trial for larsucosterol in AH in 2025, contingent on securing additional funding, with topline results expected within two years of trial start.

• The company expects operating expenses and cash burn to decrease in the near term due to reduced headcount and R&D activity.

• Actively exploring business development and financing options to support continued larsucosterol development.